The role of Qing-gan-jian-pi decoction treatment of Barrett esophagus and the influence of the expression of CDX2, P38MAPK

The role of Qing-gan-jian-pi decoction treatment of Barrett's esophagus and the influence of the exp

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OQR-14004879

Enrollment

Unknown

Registered

2014-07-01

Start date

2014-08-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Barrett's esophagus

Interventions

A:Qing-gan -jian-pi decoction(QGJPD) + Mosapride Cit

B:Rabeprazole Sodium Enteric-coated Capsules and Mos

C:Almagate Suspension and Mosapride Citrate Dispersi

Eligibility

Age

45 Years to 72 Years

Inclusion criteria

Inclusion criteria: 1. In accordance with Barrett esophagus diagnostic criteria; 2. Conform to the principle of patients' informed consent; 3. Approved by the hospital ethics committee review.

Exclusion criteria

Exclusion criteria: 1. Do not meet the inclusion criteria. Accompanied by severe dysplasia patients; 2. Application affect curative effect of other drug or treatment in the process of treatment; 3. Combined with severe heart disease, brain, liver, kidney and other important organs of patients; 4. Cases of clinical data collection is not complete.

Design outcomes

Primary

Measure	Time frame
The clinical efficacy;Cdx2;p38MAPK;	—

Countries

Shaanxi

Contacts

Public ContactJun Wang

wangjuntaiji@126.com+86 18049629954

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026